COVID-19

Combined General Meeting of June 24, 2024

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the…

5 hours ago

Ada Health, The Most Accurate AI for Care Navigation, Expands Its Leadership Team for Strategic Growth with Product and Business Development Hires

The AI-powered symptom assessment and care navigation platform, which gives 50M+ users access to its enterprise solutions, reaches key growth…

14 hours ago

Moderna’s Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address…

23 hours ago

Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference

New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism ANN ARBOR, MI /…

23 hours ago

Telehealth System Featuring Rokid Glass 2 Wins HHS Award

HANGZHOU, China, June 5, 2024 /PRNewswire/ -- Rokid's augmented reality (AR) devices are making significant inroads into the medical sector. Utilizing…

1 day ago

Masimo Joins Forces with the Mobilize Recovery 2024 Bus Tour

Collaborative Partnership Designed to Enhance Nationwide Efforts to Combat the Opioid Epidemic and Improve Addiction RecoveryIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI),…

2 days ago

First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON,…

2 days ago

Intuitive Announces FDA Clearance of Revised da Vinci Xi and X Labeling on Radical Prostatectomy

FDA review of historic data shows patients who received robotic prostatectomies have overall cancer survival rates on par with open…

2 days ago

Theralase(R) Technology Effective in Virus Inactivation

TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

3 days ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT…

3 days ago